In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Survey Says: More Work Needed To Translate Part D To Potential Enrollees

This article was originally published in The Pink Sheet Daily

Executive Summary

Proliferation of printed information about Medicare drug benefit yields no vast growth in understanding among seniors compared with last year, Kaiser Family Foundation survey results suggest.

You may also be interested in...



Medicare Drug Plan Marketing Guidelines Bolster Financial Conflict-Of-Interest Safeguards

Document clarifies role of "independent agents and brokers" under performance-based compensation system.

Part D Enrollment Deadline Approaches With Fewer Than 6 Mil. Eligibles Still Unenrolled

The federal government is on the verge of ensuring that 90% of Medicare-eligible people receive prescription drug coverage, HHS Secretary Leavitt said.

GSK Takes Cue From Schering Patient Assistance Program, Seeks Opinion From OIG

HHS Office of Inspector General will decide whether GlaxoSmithKline can donate medicines to Part D-enrolled patients.

Topics

UsernamePublicRestriction

Register

PS062784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel